Tevimbra by BeiGene for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

We wish we’d written that: STAT staffers share their favorite stories of 2024

In 2024, STAT’s reporters brought you tons of great journalism, and elsewhere [link to in-case-you-missed it] we’ve given you a compendium of the stories you

December 26, 2024

Drysdale Discusses New Investments and Cybin’s Plans

In this live-streamed episode of Trade To Black, we have a captivating interview with Doug Drysdale, the CEO of Cybin. It’s been a big week

September 20, 2023

Group Sues Tennessee Over Racial Requirements for Medical Boards

A nonprofit dedicated to opposing diversity initiatives in medicine has filed a federal lawsuit challenging the requirements surrounding the racial makeup of key medical boards

November 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.